So for someone with bibolar disorder is 150 mg of quantapine and Lithium okay

The short version: 150 mg of quetiapine plus lithium is a well-studied combination, but the lithium dose matters — it must reach a therapeutic blood level.

The evidence for quetiapine plus lithium at standard doses is real. A 2009 trial in 1,326 patients with bipolar I disorder found quetiapine (400-800 mg/day) plus lithium or divalproex significantly prolonged time to any mood recurrence compared with placebo plus a mood stabilizer, with hazard ratios of 0.23 to 0.38 depending on episode type [1]. A 4-year naturalistic study of 232 patients found quetiapine plus lithium gave the best maintenance: 80% survived without a major depressive episode, and the dropout rate was only 24%, the lowest among all groups [5].

But 150 mg of quetiapine is less than the 300-800 mg range tested in these trials [1][2]. That matters because the maintenance trials used higher doses. A 2009 trial that directly compared continued quetiapine (300-800 mg) against switching to lithium found the quetiapine arm had a significantly longer time to recurrence (HR 0.66, 95% CI 0.49-0.88, p=0.005) [2]. The lithium arm used therapeutic serum levels (0.6-1.2 mEq/L), requiring roughly 600-1200 mg/day.

The 150 mg dose may still be effective for some people, but the evidence for lower doses is thin. One small 2022 case report used quetiapine at 25 mg plus lithium 800 mg and found it ineffective [3]. A trial in adolescents used a mean dose of 340 mg [10], and another used dosing that started at 100 mg and went up to 600 mg [11]. The therapy effect appears dose-dependent: higher doses in mania showed separation from placebo by day 4, while 150 mg has not been tested in that design.

The general profile for quetiapine-plus-lithium is straightforward. A 2025 systematic review of three earlier reviews found quetiapine and lithium have similar efficacy and safety for bipolar depression [9]. Lithium remains the gold standard for manic relapse prevention, with a 27% recurrence rate over two years compared to 42% for carbamazepine in one trial [4], and is the only treatment associated with decreased risk of both psychiatric and somatic hospitalizations in a 60,000-person Finnish cohort [6]. The combination of quetiapine plus lithium has the best evidence from a 4-year naturalistic study for keeping people stable [5].

The question goes to a doctor who would prescribe this. The mix works at full doses. At 150 mg, quetiapine alone may not reach the tested range, but paired with lithium at therapeutic levels, the lithium carries the main load for mania prevention while quetiapine adds depressive-episode protection [1][5]. The key gap: no study specifically tested 150 mg quetiapine plus lithium. The 150 mg dose is common in real-world practice, often as a starting or maintenance dose after stabilization. The only safety flag from the records: consider drug interactions that can raise lithium levels, especially NSAIDs [8], and monitor serum lithium (target 0.6-1.2 mEq/L) and kidney/thyroid function [7].

My call: 150 mg of quetiapine is a lower dose than what the trials tested for maintenance, but when paired with lithium at therapeutic serum levels (roughly 600-1200 mg/day, adjusted by blood test), this is a standard combination with good evidence for preventing both manic and depressive recurrences. The 150 mg may work as a maintenance or starting dose; if it does not control symptoms, the dose can be increased. Monitor lithium levels closely.

Confidence: moderate. The combination at standard doses is well-supported by RCTs and naturalistic studies [1][2][5], but 150 mg quetiapine specifically has not been tested in those trials.